Carcinoma of the penis primary prevention: Difference between revisions
m (Robot: Automated text replacement (-mgibson@perfuse.org +charlesmichaelgibson@gmail.com & -kfeeney@perfuse.org +kfeeney@elon.edu)) |
|||
Line 1: | Line 1: | ||
{{Carcinoma of the penis}} | {{Carcinoma of the penis}} | ||
'''Editor(s)-in-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto: | '''Editor(s)-in-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com] Phone:617-632-7753; Joel Gelman, M.D. [mailto:jgelman@uci.edu], ''Director of the Center for Reconstructive Urology and Associate Clinical Professor in the Department of Urology at the University of California,Irvine'' | ||
==Overview== | ==Overview== |
Revision as of 14:17, 1 November 2012
Carcinoma of the penis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Carcinoma of the penis primary prevention On the Web |
American Roentgen Ray Society Images of Carcinoma of the penis primary prevention |
Risk calculators and risk factors for Carcinoma of the penis primary prevention |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Joel Gelman, M.D. [2], Director of the Center for Reconstructive Urology and Associate Clinical Professor in the Department of Urology at the University of California,Irvine
Overview
Vaccine
A quadri-valent vaccine to prevent HPV infection, Gardasil, has been developed, successfully tested and approved for women by the US Food and Drug Administration.[3] Approval for men is expected in 2008. It is licensed and in production, and could substantially reduce the incidence of HPV infection in men, the incidence of genital warts and ano-genital cancers including penile cancer, and mortality.[4] It is unclear why the drug's manufacturer chose to stagger testing of the vaccine, potentially leaving many men needlessly vulnerable to HPV infection.[1]